InvestSMART

Cynata Therapeutics Limited (ASX:CYP)

ALERT: Price-sensitive ASX Announcement for CYP
Current share price for CYP : $0.012 -0.248 (-95.38%)+
Release
19 Jun 2026 9:22AM
Price at Release
$0.260
Full Release
download
Summary
Cynata Therapeutics Limited (ASX: CYP) announced the reinstatement of its securities to official quotation following the release of results from its Phase 3 Osteoarthritis Trial and Phase 2 Graft versus Host Disease Trial. This announcement led to the lifting of a trading suspension by the ASX, enabling Cynata's shares to resume trading on the exchange. This marks a significant milestone in the company's clinical trial processes and ongoing efforts to advance its therapeutic offerings.
Key Points
  • Cynata Therapeutics Limited’s securities reinstated to official quotation.
  • The reinstatement follows announcements of Phase 3 Osteoarthritis Trial and Phase 2 Graft versus Host Disease Trial results.
  • Trading suspension lifted by ASX.
  • Cynata's shares resume trading on the ASX.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.